Cellectar Receives Japanese Patents

Cellectar Biosciences, a clinical stage company, said pre-market Tuesday the Japanese Patent Office has granted a method of use patent for two of the company’s phospholipid drug conjugates (PDCs). Shares were up 1.9% or four cents in recent pre-market.

These PDCs include: CLR 131, the company’s lead compound, and CLR 125, each in combination with radiation and/or other therapies to treat cancer stem cells. CLR 125 is a radiotherapeutic isotope conjugated to the company’s proprietary PDC delivery platform, which may be uniquely suited to treat select cancer and micro-metastatic disease.

Leave a Comment